Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
about
Targeting mTOR for the treatment of AML. New agents and new directionsDual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.Peripheral T cell lymphoma: new model + new insight.
P2860
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
@ast
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
@en
type
label
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
@ast
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
@en
prefLabel
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
@ast
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
@en
P2860
P356
P1433
P1476
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
@en
P2093
Cammenga J
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403894
P577
2005-10-01T00:00:00Z